Skip to Main Content

Aldeyra Therapeutics, Inc.

ALDX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
ALDX Income Statement
ALDX Balance Sheet
ALDX Cash Flow

Recent trades of ALDX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
ALDX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
ALDX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ALDX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by ALDX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Toxic aldehyde related diseases and treatment Oct. 29, 2024
  • Patent Title: Process for preparation of aldehyde scavenger and intermediates Sep. 24, 2024
  • Patent Title: Compositions and methods for the treatment of macular degeneration Sep. 24, 2024
  • Patent Title: Pharmaceutical formulations and uses thereof Aug. 20, 2024
  • Patent Title: Polymorphic compounds and uses thereof Jul. 09, 2024
  • Patent Title: Polymorphic compounds and uses thereof Jun. 11, 2024
  • Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
  • Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
  • Patent Title: Methotrexate treatment methods Feb. 27, 2024
  • Patent Title: Deuterated compounds and uses thereof Dec. 19, 2023
  • Patent Title: Ophthalmic formulations and uses thereof Oct. 17, 2023
  • Patent Title: Toxic aldehyde related diseases and treatment Oct. 03, 2023
  • Patent Title: Compositions and methods of treating retinal disease Aug. 15, 2023
  • Patent Title: Toxic aldehyde related diseases and treatment Jul. 18, 2023
  • Patent Title: Treatment of inflammatory disorders Feb. 21, 2023
  • Patent Title: Deuterated compounds and uses thereof Oct. 04, 2022
  • Patent Title: Polymorphic compounds and uses thereof Apr. 26, 2022
  • Patent Title: Formulations for treatment of dry eye disease Dec. 14, 2021
  • Patent Title: Combination treatment of ocular inflammatory disorders and diseases Sep. 28, 2021
  • Patent Title: Deuterated compounds and uses thereof Jun. 29, 2021
  • Patent Title: Treatment of inflammatory disorders Jun. 22, 2021
  • Patent Title: Toxic aldehyde related diseases and treatment May. 18, 2021
  • Patent Title: Compositions and methods of treating retinal disease Feb. 09, 2021
  • Patent Title: Toxic aldehyde related diseases and treatment Mar. 17, 2020
  • Patent Title: Deuterated compounds and uses thereof Feb. 04, 2020
  • Patent Title: Toxic aldehyde related diseases and treatment Jan. 28, 2020
  • Patent Title: Treatment of allergic eye conditions with cyclodextrins Oct. 01, 2019
  • Patent Title: Polymorphic compounds and uses thereof Sep. 17, 2019
  • Patent Title: Toxic aldehyde related diseases and treatment Feb. 26, 2019
  • Patent Title: Compositions and methods of treating retinal disease Feb. 12, 2019
  • Patent Title: Traps in the treatment of macular degeneration Oct. 30, 2018
  • Patent Title: Compositions and methods of treating retinal disease Feb. 20, 2018
  • Patent Title: Compositions and methods for the treatment of macular degeneration Nov. 14, 2017
  • Patent Title: Toxic aldehyde related diseases and treatment Jun. 27, 2017
  • Patent Title: Compositions and methods of treating retinal disease May. 16, 2017
  • Patent Title: Peri-carbinols Mar. 28, 2017
  • Patent Title: Compositions and methods of treating retinal disease Jun. 14, 2016
  • Patent Title: Compositions and methods of treating retinal disease Feb. 23, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ALDX in WallStreetBets Daily Discussion

ALDX News

Recent insights relating to ALDX

CNBC Recommendations

Recent picks made for ALDX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALDX

ALDX Top Shareholders
Shareholder
Shares Held
ALDX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ALDX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ALDX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top